Frank C Albers Selected Research

mepolizumab

3/2022	Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma.
5/2021	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
1/2021	Clinical effects of mepolizumab in patients with severe eosinophilic asthma according to background therapy: A meta-analysis.
1/2021	Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
1/2021	Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies.
1/2021	Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes.
7/2020	Response to mepolizumab treatment is sustained across 4-weekly dosing periods.
1/2020	Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.
1/2020	Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study.
1/2020	Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Frank C Albers Research Topics

Disease

35	Asthma (Bronchial Asthma) 03/2022 - 01/2017
3	Inflammation (Inflammations) 01/2022 - 01/2018
3	Chronic Obstructive Pulmonary Disease (COPD) 01/2019 - 01/2014
2	Body Weight (Weight, Body) 05/2021 - 07/2019
1	Allergic Rhinitis 05/2020
1	Parasitic Diseases (Parasitic Disease) 05/2020
1	Nasopharyngitis 01/2017
1	Headache (Headaches) 01/2017
1	Dyspnea (Shortness of Breath) 01/2014

Drug/Important Bio-Agent (IBA)

30	mepolizumabIBA 03/2022 - 01/2017
10	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021 - 01/2017
6	Omalizumab (Xolair)FDA Link 05/2021 - 01/2017
3	Budesonide (Pulmicort)FDA LinkGeneric 01/2022 - 12/2021
3	Albuterol (Salbutamol)FDA LinkGeneric 01/2022 - 12/2021
3	Bronchodilator Agents (Bronchodilators)IBA 12/2021 - 01/2021
2	GlucocorticoidsIBA 01/2022 - 10/2017
2	reslizumabIBA 01/2019 - 01/2018
2	Monoclonal AntibodiesIBA 10/2017 - 01/2017
1	3- (2- (4- azidobenzamidino)ethyl)- 5- hydroxyindole (SABA)IBA 01/2022
1	AllergensIBA 01/2021
1	Immunoglobulin E (IgE)IBA 05/2020
1	Eosinophil-Derived NeurotoxinIBA 01/2020
1	SteroidsIBA 10/2019
1	benralizumabIBA 01/2019
1	anti-IgE antibodiesIBA 01/2018
1	Biological ProductsIBA 01/2018
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	InterleukinsIBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 12/2017
1	Interleukin-5 (Interleukin 5)IBA 10/2017
1	GoldIBA 01/2014

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2017
3	Nebulizers and Vaporizers (Inhaler) 01/2022 - 01/2019
1	Biological Therapy 07/2019
1	Polypharmacy 01/2019
1	Subcutaneous Injections 10/2017